Check Out John C. Reed's LinkedIn Stats (Last 30 Days)

Recently, our R&D Senior Leadership Team had the chance to visit Johnson & Johnson sites across Europe and connect with the brilliant teams who drive and sustain our innovative pipeline. With their ingenuity and dedication, we are moving closer to addressing the needs of our global patient communities. A few highlights included: 🔴 Visited a new commercial manufacturing facility located in Sassenheim, near our facilities in Leiden, Netherlands. The site specializes in lentivirus manufacturing technology, which supports advanced oncology treatments - specifically CAR-T therapy. 🔴 Learned how our scientists in Beerse, Belgium, are pioneering novel antibody drug conjugate platforms and utilizing AI to advance the development of targeted therapies. 🔴 Met with key leaders at our London Innovation Center to discuss the abundant opportunities for harnessing external innovation from UK and Europe, as well as learning about evolution of the local biomedical research environment and emerging healthcare delivery trends. 🔴 Engaged with employees in High Wycombe, England to learn how advances in data analytics are accelerating the pace of our clinical development campaigns, discussing how we are shaping the future together as a global team. This trip was an opportunity to personally thank our teams for their ongoing successes and discuss how we’ll continue to leverage breakthrough technology in the discovery and development of transformative medicines. Thank you to all who took the time to welcome us and share how, collectively, we are pushing the limits of science to deliver for patients. #MyCompany

More than 2 million people are diagnosed with lung cancer globally each year – more than breast, colon and prostate cancers combined. Lung cancer is also the leading cause of cancer-related death in the world. At this year’s European Lung Cancer Conference, our Johnson & Johnson Oncology team was excited to share promising overall survival results for our newest treatment regimen for patients with EGFR-mutated non-small cell lung cancer (NSCLC). Patients and their families are in urgent need of treatment options that can give them more time and more hope. I’m so proud of our team for their continued commitment to pushing the bounds of what’s possible in lung cancer care. Their work could redefine the prognosis for newly diagnosed lung cancer patients and challenge the current standard of care. Learn more about our new findings: https://bit.ly/4hR7PTN #MyCompany #ELCC25 #LungCancer

At this year’s American Academy of Dermatology meeting, I was thrilled to support our team as they unveiled Johnson & Johnson’s late-breaking abstract presentation of our investigational treatment for plaque psoriasis (PsO), with a first-in-class targeted oral peptide that selectively blocks the IL-23 receptor. The robust results from our comprehensive Phase 3 study showed the once-daily pill could provide significant skin clearance and a favorable safety profile in adults and adolescents 12 years of age and older with moderate-to-severe plaque PsO. This is an exciting development that could set a new standard in treatment for plaque psoriasis, and a promising step forward in uncovering novel treatment approaches for patients living with a variety of immune-mediated diseases. https://bit.ly/43tUDjR #MyCompany #AAD2025

Dr. Paul Janssen continues to inspire our everyday efforts at Johnson & Johnson. And each year, the Dr. Paul Janssen Award for Biomedical Research recognizes scientists who share our commitment to scientific innovation and our dedication to solving healthcare challenges. It was my honor to present the award to both Dr. Lynne Maquat and Dr. Alex Varshavsky for their fundamental discoveries about regulated degradation of RNAs and proteins. Their respective research has profoundly contributed to our understanding of several cellular processes, and their work has opened avenues to the development of new treatments for many diseases. We celebrate these contributions to human health and recognize their potential to revolutionize medicine, making an impact on millions of lives. That’s Dr. Paul’s legacy—and our continued mission. Congratulations again, Drs. Maquat and Varshavsky! #MyCompany

The spirit of collaboration and trailblazing innovation at the J.P. Morgan Healthcare Conference have set the tone for a year full of promise. These are my major takeaways as we look to bring that momentum into our work in 2025: ⚡️ Partnerships: This is an area that always generates a lot of buzz at JPM, and this year was no exception. Last year, J&J executed more than 70 collaboration, licensing and acquisition agreements, demonstrating our source-agnostic approach to innovation. External innovation continues to be an area of pride for our organization, strengthening our pipeline to address critical healthcare needs. We continue to be a partner of choice in the industry, ready to join forces and improve care for the patients who are waiting. ⚡️ A.I. in biopharma: The increasing role of artificial intelligence (AI) in drug discovery and development remains a major point of conversation. Data science is already an integral part of our DNA, and I’m excited to have the expertise and leadership of our new Chief Data Officer for R&D, Belen Fraile MD, MSc, MBA, continuing our commitment to advancing healthcare with AI technology. Overall, I was thrilled with how the conference went. As we build on our momentum in 2025, I think our objectives align perfectly with where the industry’s focus lies right now. Whether it’s adding to our robust portfolio, harnessing technology to optimize drug discovery, or leveraging data to better understand disease, Johnson & Johnson Innovative Medicine is ready to seize this moment. I look forward to sharing updates on our work throughout this year. #MyCompany

2024 has been a year marked by incredible progress at Johnson & Johnson. I could not be prouder of the noble work that our team does every day to advance healthcare through the innovative medicines and medical devices that our company designs, develops, and delivers for patients around the world. Across our innovative medicine portfolio, we celebrated dozens of regulatory approvals and label expansions in major markets, backed by rigorous, high-quality clinical data that demonstrated the unequivocal benefits of our medicines for patients in need. Moreover, we shared our breakthrough science in high-impact medical journals, with hundreds of publications year to date. Without question, 2024 was an impressive year of progress for our R&D organization and the truly exciting pipeline that we are delivering for patients. We’re tackling challenging disease targets by leveraging a broad and diverse repertoire of therapeutic modalities. We’re understanding disease heterogeneity better with precision medicine approaches. We’re harnessing AI to accelerate innovation. We’re partnering with other industry collaborators to achieve more together. And we’re leveraging data at scale to accelerate our pipeline like never before. Johnson & Johnson Innovative Medicine is innovating with purpose to create life-changing therapies that help people live healthier lives. 2025 promises to be a year filled with many more opportunities to do just that. #MyCompany